J4 ›› 2010, Vol. 36 ›› Issue (6): 1026-1029.

Previous Articles     Next Articles

Effect of poly(ADP-ribose) glycohydrolase inhibitor gallotannin on renal lesion in experimental diabetic rats and its mechanism

 QU Meng1,2, ZHAO Li-Yan3, LI Cai1, LI Xiang-Jun1, SUN Bei1, WEI Hai-Feng1   

  1. (1. Department of Experimental Pharmacology and Toxicology,School of Pharmacy,Jilin University,Changchun 130021,China;2.Department of Molecular Biology,School of Ecsomatics Medical Sciences,Beihua University,Jilin 132001,China;3.Department of Laboratory,Second Hospital,Jilin University,Changchun 130041,China)
  • Received:2010-07-02 Online:2010-11-28 Published:2010-11-28

Abstract:

To investigate the effect of poly (ADP-ribose) glycohydrolase (PARG) inhibitor gallotannin on renal lesion in STZ-induced diabetic rats and its mechanism. Methods Wistar rats were randomly divided into five groups: normal control (NC) group,STZ-induced diabetic(DM)  group,diabetic rats treated with 3-aminobenzamide (CDT) group,diabetic rats treated with gallotannin 20 and 30  mg·kg-1·d-1( LDT and HDT) groups. The levels of blood glucose,serum creatinine,blood urea nitrogen,urinary protein excretion were detected after treatment for 12 weeks.The  renal morphology was observed and the expression of poly (ADP-ribose) polymerase (PARP) was tested by immunohistochemical method. Results Compared with DM group,the levels of blood glucose,serum creatinine,blood urea nitrogen  and urinary protein excretion were significantly decreased in both LDT and HDT groups(P<0.05 or P<0.01). The renal lesion and the signal of positive expressing PARP in renal tissues were markedly reduced in diabetic rats treated with GLTN.But there were no significant differences of the indexes mentioned above between LDT and HDT groups(P>0.05).Conclusion Gallotannin can lower the level of blood glucose,inhibit the  renal PARP expression,and ameliorate the renal functional and morphological abnormalities in diabetic rats.

Key words: gallotannin;poly (ADP-ribose) glycohydrolase;poly (ADP-ribose) polymerase;diabetic nephropathy

CLC Number: 

  • R587.1